PT - JOURNAL ARTICLE AU - Jules R. Dugré AU - Stéphane Potvin TI - Neural bases of Frustration-Aggression Theory: A multi-domain meta-analysis of functional neuroimaging studies AID - 10.1101/2021.05.12.21257119 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.12.21257119 4099 - http://medrxiv.org/content/early/2021/05/19/2021.05.12.21257119.short 4100 - http://medrxiv.org/content/early/2021/05/19/2021.05.12.21257119.full AB - Early evidence suggests that unexpected non-reward may increase the risk for aggressive behaviors. Despite the growing interest in understanding brain functions that may be implicated in aggressive behaviors, the neural processes underlying such frustrative events remain largely unknown. Furthermore, meta-analytic results have produced discrepant results, potentially due to substantial differences in the definition of anger/aggression constructs. Therefore, coordinate-based meta-analyses on unexpected non-reward and retaliatory behaviors in healthy subjects were conducted. Conjunction analyses were further examined to discover overlapping brain activations across these meta-analytical maps. Frustrative non-reward deactivated the orbitofrontal cortex, ventral striatum and posterior cingulate cortex, whereas increased activations were observed in midcingulo-insular regions, as well as dorsomedial prefrontal cortex, amygdala, thalamus and periaqueductal gray, when using liberal threshold. Retaliation activated of midcingulo-insular regions, the dorsal caudate and the primary somatosensory cortex. Conjunction analyses revealed that both strongly activated midcingulo-insular regions. Our results underscore the role of anterior midcingulate/pre-supplementary motor area and fronto-insular cortex in both frustration and retaliatory behaviors. A neurobiological framework for understanding frustration-based impulsive aggression is provided.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJRD is holder of a scholarship from the Fonds de Recherche du Quebec en Sante (FRQS). SP is holder of the Eli Lilly Canada Chair on Schizophrenia Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon reasonable request from the corresponding authors.